Veru Inc. (VERU) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Veru (VERU) Q2 2026: R&D Spend Falls 53% as Obesity Pipeline Focus Sharpens
June 17, 2026
-
Veru (VERU) Q3 2025: Phase IIb Data Drives 46% Reduction in Post-GLP-1 Weight Regain, FDA Clarity Looms
June 16, 2026
-
Veru (VERU) Q4 2025: $23M Capital Raise Extends Obesity Platform Runway Through Pivotal Plateau Trial
June 15, 2026